Related Experiment Videos
[Ocular findings in Desferal therapy]
J A Dennerlein1, G E Lang, K Stahnke
1Universitäts-Augenklinik und Poliklinik, Ulm.
Summary
Desferrioxamine (DFO) treatment for thalassemia can cause ocular side effects, including lens opacities and retinal changes. These vision problems are dose-dependent and may improve after stopping DFO therapy.
Area of Science:
- Ophthalmology
- Hematology
- Pharmacology
Context:
- Desferrioxamine (DFO) is a critical iron-chelating agent for managing thalassemia major and transfusion-dependent anemias.
- Excess iron accumulation in these conditions can lead to severe systemic complications.
- Understanding DFO's potential toxicities is crucial for patient management.
Purpose:
- To prospectively evaluate the ocular side effects associated with Desferrioxamine (DFO) treatment in young patients.
- To identify specific ophthalmological changes and their prevalence in patients receiving DFO therapy.
- To assess the relationship between DFO treatment and visual function.
Summary:
- Ophthalmological examinations were conducted on 17 patients (ages 5-25) undergoing DFO treatment.
- Prevalence of ocular findings included lens opacities (41%), retinal pigment epithelium changes (35%), and visual function deficits (color vision, dark adaptation).
- DFO-induced oculotoxicity appears dose-dependent, with some visual acuity impairments showing partial reversibility upon treatment cessation.
Impact:
- Highlights the significant risk of ocular toxicity from Desferrioxamine (DFO) therapy.
- Emphasizes the necessity for regular ophthalmological monitoring in patients receiving DFO.
- Informs clinical practice regarding the potential for reversible visual impairments and the importance of dose management.